Clinical Kidney Journal · 2024 · 10 citations · 5 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyDialysisRenal PharmacotherapyChronic Kidney DiseaseRenal DiseaseRenal Function TestsRenal PharmacologySodium-glucose Cotransporter 2 InhibitorsChronic Kidney Disease StagingCkd ProgressionCkd StagingDiscontinuation DecisionsReal-world Safety DataRenal Drug SafetySodium-glucose CotransportSodium-glucose Cotransporter 2 Inhibition
To the Editor, Recent randomized trials [1 , 2 ] have demonstrated the renal and cardiovascular benefit of sodium-glucose cotransporter 2 inhibitors ( SGLT2i) in chronic kidney disease ( CKD) patients, irrespective of diabetes status.However, real-world data on their use in advanced CKD stages remain scarce.This study aims to assess the safety and discontinuation reasons of SGLT2i in this demographic.We conducted a retrospective analysis of 271 patients with stage 4 and non-dialysed stage 5 CKD, from January 2020 to December 2022, across five nephrology units ( CKD-REAL study) .The median initiation of SGLT2i was 356 days post-stage 4 diagnosis, predominantly with dapagliflozin ( 266 patients) and empagliflozin ( six patients) .Safety profiles and eGFR trajectories were monitored at 6 and 12 months, with a minimum followup of 6 months.
5
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine · 2020 · 5.2K citations · Full text
Empagliflozin in Patients with Chronic Kidney Disease
New England Journal of Medicine · 2022 · 2.4K citations · Full text
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
Glenn M. Chertow, Priya Vart, Niels Jongs et al. · UCL Discovery (University College London) · 2021 · 101 citations